Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Indoramin 20 mg Tablet

Active Ingredient:
indoramin hydrochloride
Brown & Burk UK Ltd See contact details
About Medicine
{healthcare_pro_orange} This information is for use by healthcare professionals
Last updated on emc: 24 Sep 2021
1. Name of the medicinal product

Indoramin 20 mg Tablets

2. Qualitative and quantitative composition

Each tablet contains '22 mg' of Indoramin hydrochloride equivalent to 20 mg of Indoramin.

Excipient(s) with known effect:

Each film-coated tablet contains '172.2mg' of lactose (as lactose monohydrate). For the full list of excipients, see section 6.1.

3. Pharmaceutical form

Film coated tablet.

Pale yellow, triangular, biconvex, film coated tablets embossed with a key on both sides.

4. Clinical particulars
4.1 Therapeutic indications

Indoramin is indicated in adults for conditions in which alpha blockade is indicated and the management of urinary outflow obstruction due to benign prostatic hyperplasia.

4.2 Posology and method of administration



20 mg twice daily

Dosage may be increased in 20 mg increments at two-weekly intervals up to max. 100 mg per day if required.


20 mg at night may be adequate.

Paediatric population

Not recommended. There is no relevant use of indoramin in the paediatric population

Route of administration


4.3 Contraindications

Patients with established heart failure.

Patients already under treatment with a monoamine oxidase inhibitor.

4.4 Special warnings and precautions for use

Special warnings

Incipient cardiac failure should be controlled before treatment with indoramin.

Caution should be observed in prescribing indoramin for patients with hepatic or renal insufficiency.

A few cases of extrapyramidal disorders have been reported in patients treated with indoramin. Caution should be observed in prescribing indoramin in patients with Parkinson's disease.

In animals and in the one reported case of overdose in humans, convulsions have occurred. Due consideration should be given and great caution exercised in the use of indoramin in patients with epilepsy.

The 'Intraoperative Floppy Iris Syndrome' (IFIS, a variant of small pupil syndrome) has been observed during cataract surgery in some patients on or previously treated with tamsulosin. Isolated reports have also been received with other alpha-1 blockers and the possibility of a class effect cannot be excluded. As IFIS may lead to increased procedural complications during the cataract operation current or part use of alpha-1 blockers should be made known to the ophthalmic surgeon in advance of surgery.

Caution should be observed in prescribing indoramin for patients with a history of depression.

Clearance of indoramin may be affected in the elderly. A reduced dose, and/or reduced frequency of dosing may be sufficient in some elderly patients.

Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose -malabsorption should not take this medicine.

4.5 Interaction with other medicinal products and other forms of interaction

Do not use indoramin in patients being treated with a monoamine oxidase (MAO) inhibitor.

Concomitant use of indoramin with antihypertensive drugs or drugs with hypotensive properties e.g. antidepressants, anxiolytics, hypnotics and moxisylyte, may enhance their hypotensive action. Titration of dosage of the latter may therefore be needed.

Alcohol can increase both the rate and extent of absorption of indoramin, but no untoward effects have been reported at recommended doses.

4.6 Fertility, pregnancy and lactation

There are no data from the use of indoramin in pregnant women. Indoramin is not recommended during pregnancy and in women of child bearing potential not using contraception.

It is unknown whether indoramin/ metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded.

A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from indoramin therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.

4.7 Effects on ability to drive and use machines

Drowsiness is sometimes seen in the initial stages of treatment with indoramin or when dosage is increased too rapidly. If drowsiness occurs, patients should be warned not to drive or operate machinery and to avoid CNS depressants including alcohol.

4.8 Undesirable effects

In general, indoramin is well tolerated.

The following undesirable effects have been observed and reported during treatment with indoramin with the following frequencies: Very common (≥ 1/10); common (≥ 1/100 to <1/10); uncommon (≥ 1/1,000 to <1/100); rare (≥ 1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).

MedDRA System Organ Class


Undesirable effects

Immune system disorders



Psychiatric disorders



Nervous system disorders



Parkinson's disease





Vascular disorders


Hypotension, with or without syncope

Orthostatic hypotension

Respiratory, thoracic and mediastinal disorders


Nasal congestion

Gastrointestinal disorders


Dry mouth

Skin and subcutaneous tissue disorders




Reproductive system and breast disorders


Ejaculation failure

General disorders and administration site conditions





Weight increased

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at:

4.9 Overdose

Information available at present of the effects of acute overdosage in human beings with indoramin is limited. Effects seen have included deep sedation leading to coma, hypotension and fits.

In cases of overdose QTc prolongation can occur, sometimes complicated by severe arrhythmias, such as Torsades de Pointes.

Results of animal work suggest that hypothermia may also occur.

Suggested therapy is along the following lines:

1. Recent ingestion of large numbers of tablets would require gastric lavage or a dose of ipecacuanha to remove any of the product still in the stomach of the conscious patient.

2. Cardiac monitoring should be initiated immediately and continued for at least 24 hours.

3. Ventilation should be monitored and assisted if necessary.

4. Circulation support and control of hypotension should be maintained.

5. If convulsions occur diazepam may be tried.

Temperature should be closely monitored. If hypothermia occurs, rewarming should be carried out very slowly to avoid possible convulsions.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Alpha adrenoreceptor antagonist.

Indoramin is an alpha adrenoceptor blocking agent. It acts selectively and competitively on post-synaptic alpha-1 receptors, causing a decrease in peripheral resistance. It also produces relaxation of hyperplastic muscle in the prostate.

5.2 Pharmacokinetic properties

Indoramin is rapidly absorbed from Indoramin tablets and has a half-life of about five hours. There is little accumulation during long-term treatment. When three volunteers and four hypertensive patients were treated with radiolabelled indoramin at doses of 40-60 mg daily for up to three days, plasma concentrations reached a peak one to two hours after administration of single doses. Over 90% of plasma indoramin was protein bound. After two or three days 35% of the radioactivity was excreted in the urine and 46% in the faeces. Extensive first pass metabolism was suggested.

Clearance of indoramin may be affected in the elderly. A reduced dose or reduced frequency of dosing may be sufficient in some elderly patients.

5.3 Preclinical safety data

Not applicable.

6. Pharmaceutical particulars
6.1 List of excipients

Tablet core

Lactose Monohydrate

Microcrystalline Cellulose

Magnesium Stearate

Polacrillin potassium

Tablet film coat

Opadry yellow 02B520014 which consists of


Titanium dioxide (E 171)

Polyethylene glycol

Yellow iron oxide (E172)

Black iron oxide (E172)

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

36 months.

6.4 Special precautions for storage

This medicinal product does not require any special storage conditions.

6.5 Nature and contents of container

Tablets are packed in PVC/PVDC – Alu blisters containing 28, 30, 56, 60 & 84 tablets.

6.6 Special precautions for disposal and other handling

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. Marketing authorisation holder

Brown & Burk UK Ltd

5 Marryat Close

Hounslow West



United Kingdom

8. Marketing authorisation number(s)

PL 25298/0156

9. Date of first authorisation/renewal of the authorisation

08/12/2014 / 23/01/2020

10. Date of revision of the text


Brown & Burk UK Ltd
Company image
Brown & Burk UK Limited, Micro House, Bury Street, Ruislip, HA4 7TL, UK
+44 (0)203 384 7188
+44 (0)208 588 5411
Medical Information Direct Line
+44 (0)203 384 7188
Medical Information e-mail
[email protected]
Customer Care direct line
+44 (0)203 384 7188
Medical Information Fax
+44 (0)208 588 5411
Stock Availability
+44 (0)203 384 7188